Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.35 |
| ▸ | USP2 | O75604 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 4/20 | 0.33 |
| ▸ | GALR3 | O60755 | 2/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9823979 | 0.84 | GABRP (0.41) | TDP1ALDH1A1HSD17B10LMNACYP3A4 | |
| SCHEMBL888659 | 0.82 | ALDH1A1 (0.50) | TDP1ALDH1A1HSD17B10LMNAHPGD | |
| SCHEMBL13300353 | 0.81 | ALDH1A1 (0.46) | TDP1ALDH1A1HSD17B10LMNAHPGD | |
| SCHEMBL13459987 | 0.80 | TDP1 (0.45) | TDP1ALDH1A1HSD17B10LMNAHPGD | |
| SCHEMBL5358516 | 0.80 | TDP1 (0.45) | TDP1ALDH1A1HSD17B10LMNAHPGD | |
| SCHEMBL13479158 | 0.79 | TDP1 (0.41) | TDP1ALDH1A1HSD17B10LMNAHPGD | |
| SCHEMBL5930106 | 0.79 | TDP1 (0.45) | TDP1ALDH1A1HSD17B10LMNAHPGD | |
| SCHEMBL8336829 | 0.79 | TDP1 (0.41) | TDP1ALDH1A1HSD17B10LMNAHPGD | |
| SCHEMBL7816892 | 0.79 | TDP1 (0.41) | TDP1ALDH1A1HSD17B10LMNAHPGD | |
| SCHEMBL6916715 | 0.79 | TDP1 (0.41) | TDP1ALDH1A1HSD17B10LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108484605-B | Preparation method of 2-amino-6-chloro-9- (4-acetoxyl-3-acetoxymethyl butyl) purine | 上药康丽（常州）药业有限公司 | 2020-08-21 | — | — | CN | claimed |
| EP-0141927-B1 | ANTIVIRAL GUANINE DERIVATIVES | BEECHAM GROUP PLC (GB) | 1991-10-30 | — | — | EP | claimed |
| CN-108484605-B | Preparation method of 2-amino-6-chloro-9- (4-acetoxyl-3-acetoxymethyl butyl) purine | 上药康丽（常州）药业有限公司 | 2020-08-21 | — | — | CN | disclosed |
| CN-108484605-B | Preparation method of 2-amino-6-chloro-9- (4-acetoxyl-3-acetoxymethyl butyl) purine | 上药康丽（常州）药业有限公司 | 2020-08-21 | — | — | CN | disclosed |
| US-9549930-B2 | Combined systemic and topical treatment of disordered and/or prodromal stage tissue | QUADEX PHARMACEUTICALS, LLC (US) | 2017-01-24 | — | — | US | disclosed |
| US-9545408-B2 | Combined systemic and topical treatment of disordered tissues | QUADEX PHARMACEUTICALS, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| EP-2968228-A1 | COMBINED SYSTEMIC AND TOPICAL TREATMENT OF DISORDERED TISSUES | Quadex Pharmaceuticals, LLC (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150374704-A1 | COMBINED SYSTEMIC AND TOPICAL TREATMENT OF DISORDERED AND/OR PRODROMAL STAGE TISSUE | QUADEX PHARMACEUTICALS, LLC | 2015-12-31 | — | — | US | disclosed |
| US-20150342955-A1 | COMBINED SYSTEMIC AND TOPICAL TREATMENT OF DISORDERED TISSUES | QUADEX PHARMACEUTICALS, LLC | 2015-12-03 | — | — | US | disclosed |
| US-9125911-B2 | Combined systemic and topical treatment of disordered tissues | QUADEX PHARMACEUTICALS, LLC (US) | 2015-09-08 | — | — | US | disclosed |
| EP-2846788-A1 | USE OF COMPOUNDS FOR THE TREATMENT OF PAIN | Akron Molecules AG (AT) | 2015-03-18 | — | — | EP | disclosed |
| US-5656617-A | ANTIVIRAL AGENT | MEDIVIR AB (SE) | 1997-08-12 | — | — | US | disclosed |
| US-5565461-A | TREATING HUMAN IMMUNODEFICIENCY VIRUS | MEDIVIR AB (SE) | 1996-10-15 | — | — | US | disclosed |
| US-5284837-A | Viricides | MEDIVIR AB (SE) | 1994-02-08 | — | — | US | disclosed |
| EP-0343133-B1 | DERIVATIVES OF PURINE, PROCESS FOR THEIR PREPARATION AND A PHARMACEUTICAL PREPARATION | Medivir Aktiebolag (SE) | 1992-04-08 | — | — | EP | disclosed |
| US-5075445-A | GUANINE DERIVATIVES | BEECHAM GROUP P.L.C. (GB) | 1991-12-24 | — | — | US | disclosed |
| EP-0141927-B1 | ANTIVIRAL GUANINE DERIVATIVES | BEECHAM GROUP PLC (GB) | 1991-10-30 | — | — | EP | disclosed |
| EP-0343133-A1 | Derivatives of purine, process for their preparation and a pharmaceutical preparation | Medivir Aktiebolag (SE) | 1989-11-23 | — | — | EP | disclosed |
| WO-1989010923-A1 | DERIVATIVES OF PURINE, PROCESS FOR THEIR PREPARATION AND A PHARMACEUTICAL PREPARATION | MEDIVIR AB (SE) | 1989-11-16 | — | — | WO | disclosed |
| EP-0141927-A2 | Antiviral guanine derivatives | BEECHAM GROUP PLC (GB) | 1985-05-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150342955-A1 | COMBINED SYSTEMIC AND TOPICAL TREATMENT OF DISORDERED TISSUES | NT5E, SAMHD1, DCTD | TDP1 251/4885ALDH1A1 3897/4885HSD17B10 3879/4885 |
| US-20150374704-A1 | COMBINED SYSTEMIC AND TOPICAL TREATMENT OF DISORDERED AND/OR PRODROMAL STAGE TISSUE | SAMHD1, CUTA, TK1 | TDP1 287/4885ALDH1A1 4317/4885HSD17B10 4458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.